Who is â€~Mollyâ€?MDMA adulterants by product nan services at raves

Journal of Psychopharmacology 31, 1056-1060

DOI: 10.1177/0269881117715596

Citation Report

#	Article	IF	CITATIONS
1	Deaths related to MDMA (ecstasy/molly): Prevalence, root causes, and harm reduction interventions. Journal of Substance Use, 2018, 23, 345-352.	0.3	23
2	"Ecstasy―to addiction: Mechanisms and reinforcing effects of three synthetic cathinone analogs of MDMA. Neuropharmacology, 2018, 133, 171-180.	2.0	31
3	Spore forming bacteria infections and people who inject drugs: Implications for harm reduction. International Journal of Drug Policy, 2018, 53, 45-54.	1.6	2
4	Use of synthetic stimulants and hallucinogens in a cohort of electronic dance music festival attendees. Forensic Science International, 2018, 282, 168-178.	1.3	60
5	The Detection of Novel Stimulants in Oral Fluid from Users Reporting Ecstasy, Molly and MDMA Ingestion. Journal of Analytical Toxicology, 2018, 42, 544-553.	1.7	33
6	Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats. Psychopharmacology, 2018, 235, 3233-3241.	1.5	4
7	Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology, 2018, 9, 733.	1.6	115
8	Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chemical Neuroscience, 2018, 9, 2408-2427.	1.7	50
9	Evaluation of a drug checking service at a large scale electronic music festival in Portugal. International Journal of Drug Policy, 2019, 73, 88-95.	1.6	43
10	Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence. Harm Reduction Journal, 2019, 16, 39.	1.3	56
11	Pillâ€testing as a harm reduction strategy: time to have the conversation. Medical Journal of Australia, 2019, 211, 447.	0.8	6
12	Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 $\hat{a} \in A$ potential risk to users?. Drug Testing and Analysis, 2019, 11, 1172-1182.	1.6	23
13	Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances. Future Medicinal Chemistry, 2019, 11, 161-164.	1.1	2
14	The spurious relationship between ecstasy use and neurocognitive deficits: A Bradford Hill review. International Journal of Drug Policy, 2019, 64, 47-53.	1.6	11
15	Synthetic cathinone adulteration of illegal drugs. Psychopharmacology, 2019, 236, 869-879.	1.5	49
16	Drug safety testing, disposals and dealing in an English field: Exploring the operational and behavioural outcomes of the UK's first onsite â€~drug checking' service. International Journal of Drug Policy, 2019, 67, 102-107.	1.6	109
17	Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States. International Journal of Drug Policy, 2019, 63, 122-128.	1.6	189
18	Willingness to Provide a Hair Sample for Drug Testing among Electronic Dance Music Party Attendees. Substance Abuse, 2019, 40, 116-123.	1.1	8

#	Article	IF	CITATIONS
19	Keynote Address 2018 Southern Maine Harm Reduction Conference. Deviant Behavior, 2020, 41, 905-912.	1.1	0
20	City checking: Piloting the UK's first communityâ€based drug safety testing (<i>drug checking</i>) service in 2 city centres. British Journal of Clinical Pharmacology, 2020, 86, 420-428.	1.1	52
21	The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants. Drug and Alcohol Dependence, 2020, 208, 107772.	1.6	4
22	Drug Checking and Its Potential Impact on Substance Use. European Addiction Research, 2021, 27, 25-32.	1.3	19
23	Drug Checking as Strategy for Harm Reduction in Recreational Contests: Evaluation of Two Different Drug Analysis Methodologies. Frontiers in Psychiatry, 2021, 12, 596895.	1.3	17
24	Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Scientific Reports, 2021, 11, 5997.	1.6	19
25	Could a drugâ€checking service increase intention to use ecstasy at a festival?. Drug and Alcohol Review, 2021, 40, 974-978.	1.1	8
26	Intentions, actions and outcomes: A follow up survey on harm reduction practices after using an English festival drug checking service. International Journal of Drug Policy, 2021, 95, 103270.	1.6	39
27	Delivering harm reduction to the community and frontline medical practitioners through the South Australian Drug Early Warning System (SADEWS). Forensic Science, Medicine, and Pathology, 2021, 17, 388-394.	0.6	11
28	The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity Experimental and Clinical Psychopharmacology, 2021, 29, 219-228.	1.3	5
29	Drug checking at dance festivals: A review with recommendations to increase generalizability of findings Experimental and Clinical Psychopharmacology, 2021, 29, 229-235.	1.3	29
30	Consumer discernment of fentanyl in illicit opioids confirmed by fentanyl test strips: Lessons from a syringe services program in North Carolina. International Journal of Drug Policy, 2021, 93, 103128.	1.6	18
31	Interpol review of controlled substances 2016–2019. Forensic Science International (Online), 2020, 2, 608-669.	0.6	13
32	What About Drug Checking? Systematic Review and Netnographic Analysis of Social Media. Current Neuropharmacology, 2020, 18, 906-917.	1.4	9
33	Drug checking services for people who use drugs: a systematic review. Addiction, 2022, 117, 532-544.	1.7	90
34	Self-reported Subjective Effects of Analytically Confirmed New Psychoactive Substances Consumed by e-Psychonauts: Protocol for a Longitudinal Study Using a New Internet-Based Methodology. JMIR Research Protocols, 2021, 10, e24433.	0.5	3
35	Anxiety-related Symptoms following the Sporadic Use of Ecstasy – A Case Study. Journal of Psychoactive Drugs, 2022, 54, 378-385.	1.0	1
36	Retrospective suspect and non-target screening combined with similarity measures to prioritize MDMA and amphetamine synthesis markers in wastewater. Science of the Total Environment, 2022, 811, 152139.	3.9	5

3

#	ARTICLE	IF	CITATIONS
37	Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. Journal of Psychopharmacology, 2022, 36, 57-65.	2.0	22
38	MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. Journal of Psychopharmacology, 2022, 36, 46-56.	2.0	28
39	Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology, 2022, 239, 1945-1976.	1.5	25
40	Fentanyl Contamination as a Risk Priority: the Impact of the Fentanyl Epidemic on Club Drug-Using Behaviours. Substance Use and Misuse, 2022, 57, 975-982.	0.7	1
41	Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results. Journal of Neuropsychiatry and Clinical Neurosciences, 2023, 35, 77-85.	0.9	1
42	Methylone Pre-Exposure Differentially Impacts the Aversive Effects of MDPV and MDMA in Male and Female Sprague-Dawley Rats: Implications for Abuse Vulnerability. SSRN Electronic Journal, 0, , .	0.4	0
43	Substance residue analysis as an alternative to drug checking? Traces from drug paraphernalia as a source for laboratory analysis., 2022, 23, 277-288.		2
44	Comparative harms assessments for cannabis, alcohol, and tobacco: Risk for psychosis, cognitive impairment, and traffic accident. Drug Science, Policy and Law, 2022, 8, 205032452210952.	0.6	4
45	Assessment of MDMA tablet and capsule dosages from seizures in Queensland, Australia. Forensic Chemistry, 2022, 31, 100453.	1.7	2
46	Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample. Journal of Psychopharmacology, 2022, 36, 1129-1135.	2.0	2
47	Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and) Tj ETQq0 0	0 г <u>е</u> ВТ /О	verJock 10 Tf
48	Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Scientific Reports, 2022, 12, .	1.6	16
49	Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances. International Journal of Molecular Sciences, 2022, 23, 14619.	1.8	4
50	Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample. Scientific Reports, 2023, 13, .	1.6	1
58	Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances. , 2023, , 1-34.		0